z-logo
open-access-imgOpen Access
Inhibition of Dopamine β-Hydroxylase in Blood Vessels by Picolinic Acid Derivatives in vivo and their Antihypertensive Effects
Author(s) -
Hiroyoshi Hidaka,
Fumiko Shoka,
Yoshio Hashizume,
Nobutaka Takemoto,
Masahiro Yamamoto
Publication year - 1975
Publication title -
japanese journal of pharmacology/japanese journal of pharmacology
Language(s) - English
Resource type - Journals
eISSN - 1347-3506
pISSN - 0021-5198
DOI - 10.1254/jjp.25.515
Subject(s) - picolinic acid , aorta , dopamine , chemistry , in vivo , mesenteric arteries , endocrinology , renal artery , medicine , artery , inferior mesenteric artery , norepinephrine , blood pressure , tyramine , kidney , biochemistry , anatomy , biology , microbiology and biotechnology
The effect of picolinic acid derivatives, 5-butylpicolinic (fusaric) acid (FA), 5-(3',4'-DIBROMOBUTYL)PICOLINIC ACID(BPR2FA)and 50(N'N-dimethyldithiocarbamoilmethyl)picolinic acid (YP-279) on dopamine beta-hydroxylase in blood vessels in vivo was studied. Maximum inhibition of the conversion of 14C-dopamine (14C-DA) to 14C-norepinephrine (14C-ne) in rat aorta, mesenteric artery and renal artery was detected 30 min after FA and Br2FA (75 mg/kg) and 60 min after YP-279 (75 MG/KG). NE synthesis from 14C-DA returned to near control values by 6 hr in the blood vessels. NE levels of the aorta and mesenteric artery were sigkificantly reduced by 30 to 50% at 4 hr after Br2FA or FA (75 mg/kg). Dopamine beta-hydroxylase (DBH) activity, using tyramine as substrate, in heart, aorta, mesenteric artery and renal artery was markedly reduced. The concentrations of FA, Br2FA and YP-279 in rat blood following a single i.p, injection of each drug increase rapidly, reaching highest values in 0 to 30 min and decreasing slowly to 0 after 6 hr. These compounds did not affect the uptake of 3H-NE into the rat heart. These three compounds were found to lower blood pressure effectively in normal Wistar rats (above 25 mg/kg).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here